ENO1 and gastric cancer: The study demonstrates that circUBE2G1-99aa is downregulated in GC and suppresses tumor progression by binding to the catalytic TIM barrel domain of ENO1, thereby inhibiting its enzymatic activity and glycolysis (Fig. 6F).